Abstract
We have discovered a non-AT1, non-AT2 angiotensin binding site in rodent and human brain membranes, which, based on its pharmacological/biochemical properties and tissue distribution, is different from angiotensin receptors and key proteases processing angiotensins. In this study, the novel angiotensin binding site was localized to a specific brain cell type by using radioligand receptor binding assays. Our results indicate that the novel binding site is expressed in mouse primary cortical neuronal membranes but not in primary cortical astroglial and bEnd.3 brain capillary endothelial cell membranes. Whole-cell binding assays in neurons showed that the binding site faces the outer side of the plasma membrane. Consistent with our previous observations, the novel binding site was unmasked by the sulfhydryl reagent p-chloromercuribenzoate. This effect had a bell-shaped curve and was reversed by reduced glutathione, indicating that the function of the binding site might be regulated by the redox state of the environment. Density of the novel binding site measured by saturation binding assays was significantly increased in neuronal membranes of cells challenged in four in vitro models of cell death (oxygen-glucose deprivation, sodium azide-induced hypoxia, N-methyl-d-aspartate neurotoxicity, and hydrogen peroxide neurotoxicity). In addition, our in vivo data from developing mouse brains showed that the density of the novel angiotensin binding site changes similarly to the pattern of neuronal death in maturating brain. This is the first time that evidence is provided on the association of the novel angiotensin binding site with neuronal death, and future studies directed toward understanding of the functions of this protein are warranted.
Footnotes
This work was supported by Texas Tech University Health Sciences Center School of Pharmacy start-up funds (to V.T.K.).
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.110.171439.
-
ABBREVIATIONS:
- RAS
- renin-angiotensin system
- AngII
- angiotensin II
- SI-AngII
- Sar1-Ile8 angiotensin II
- ZD7155
- 5,7-diethyl-3,4-dihydro-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,6-naphthyridin-2(1H)-one hydrochloride
- PD123319
- 1-[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid ditrifluoroacetate
- PCMB
- p-chloromercuribenzoate
- PCMPS
- p-chloromercuri-benzenesulfonate
- MTT
- 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
- GSH
- glutathione
- GSSG
- oxidized glutathione
- HBSS
- Hanks' buffered salt solution
- EBSS
- Earle's balanced salt solution
- En
- embryonic day n
- Pn
- postnatal day n
- NMDA
- N-methyl-d-aspartate
- LDH
- lactate dehydrogenase.
- Received June 12, 2010.
- Accepted September 21, 2010.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|